Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,417
Total Claims
$708K
Drug Cost
577
Beneficiaries
$1,227
Cost/Patient
Risk Score Breakdown 6/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-13%
Cost per patient vs peers
$1,227 vs $1,411 avg
-10%
Brand preference vs peers
9.6% vs 10.6% avg
Brand vs Generic
Brand: 902 claims · $535K
Generic: 8,498 claims · $172K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Tirzepatide | 54 | $64K |
| Empagliflozin | 78 | $58K |
| Apixaban | 77 | $58K |
| Dapagliflozin Propanediol | 36 | $47K |
| Semaglutide | 40 | $39K |
| Dulaglutide | 20 | $33K |
| Rivaroxaban | 37 | $31K |
| Sacubitril/Valsartan | 34 | $29K |
| Sitagliptin Phosphate | 26 | $20K |
| Linagliptin | 20 | $17K |
| Sitagliptin Phos/Metformin Hcl | 18 | $15K |
| Fluticasone Propion/Salmeterol | 16 | $9,463 |
| Nebivolol Hcl | 96 | $8,685 |
| Telmisartan | 161 | $7,446 |
| Rosuvastatin Calcium | 426 | $7,137 |
Prescribing Profile
Patient Profile
76
Avg Age
52%
Female
1.01
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data